Skip to main content

Table 1 Demographic data of study patients

From: Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)

    

N (Percent %)

Total number of patients = 60

Gender

Female

10(16.7%)

 

Male

50(83.3%)

Smoking

Ex-smoker

33(55.0%)

 

Non-smoker

9(15.0%)

 

Smoker

18(30.0%)

No. of tumors

2-7

57(95.0%)

 

>8

3(5.0%)

Stage

Primary CIS

2(3.3%)

 

T1

24(40.0%)

 

Ta

34(56.7%)

Grade

High grade

23(38.3%)

 

Low grade

37(61.7%)

Histology

Papillary

55(91.7%)

 

Concomitant CIS and papillary

3(5.0%)

 

Primary CIS

2(3.3%)

BCG

BCG Complete

42(70%)

 

BCG Termination

18(30%)

 

BCG Termination reasons

BCG Refractory

3(16.7%)

  

BCG intolerance

11(61.1%)

  

BCG resistance

2(11.1%)

  

BCG sepis

2(11.1%)

 

Median

Maximum

Minimum

Mean

Age (Years)

63

81

37

61.7

Cigarette pack-year

60

150

10

55.4

No. of BCG installation

18

18

3

15.7

Follow up time (Years)

3.98

7.8

8.28 months

4.1